X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.pharmacompass.com/pdf/news/fda-confirms-para-iv-patent-litigation-for-lasmiditan-succinate-reyvowtablets-11947.pdf
https://www.pharmacompass.com/pdf/news/eli-lillys-rayvow-lasmiditan-receives-approval-in-europe-9507.pdf
https://www.prnewswire.com/news-releases/reyvow-lasmiditan-c-v-demonstrated-superior-pain-freedom-at-2-hours-in-at-least-2-of-3-migraine-attacks-in-new-phase-3-consistency-of-effect-study-301145956.html
https://www.fiercepharma.com/pharma/eli-lilly-squaring-off-against-abbvie-and-biohaven-touts-data-showing-early-and-lasting
https://seekingalpha.com/news/3613241-lillys-migraine-med-lasmiditan-successful-in-another-late-stage-study
https://www.fiercepharma.com/pharma/final-review-icer-experts-more-favorable-allergan-biohaven-migraine-meds-but-say-lilly-s
https://www.reuters.com/article/us-lilly-fda-pricing/eli-lilly-prices-migraine-therapy-at-640-for-pack-of-eight-pills-idUSKBN1ZU29I?feedType=RSS&feedName=healthNews
https://investor.lilly.com/news-releases/news-release-details/lillys-reyvowtm-lasmiditan-c-v-first-and-only-medicine-new-class
https://www.fiercepharma.com/pharma/lilly-set-for-first-2020-launch-after-dea-scheduling-for-migraine-drug-reyvow
https://endpts.com/biohaven-celebrates-phii-iii-win-for-intranasal-cgrp-migraine-drug-amid-oral-race-with-allergan/
https://icer-review.org/announcements/icer-releases-draft-evidence-report-on-acute-migraine-therapies/
https://www.fiercepharma.com/pharma/forthcoming-migraine-meds-from-lilly-allergan-and-biohaven-don-t-offer-benefits-over-older
https://endpts.com/eli-lilly-has-anted-up-for-its-next-big-bet-on-a-next-gen-pain-drug-buying-hydra-assets/
https://www.fiercebiotech.com/biotech/lilly-files-for-fda-approval-migraine-drug-lasmiditan
https://www.prnewswire.com/news-releases/lilly-submits-new-drug-application-to-the-fda-for-lasmiditan-for-acute-treatment-of-migraine-receives-breakthrough-therapy-designation-for-emgality-galcanezumab-gnlm-for-prevention-of-episodic-cluster-headache-300750141.html
Market Place
Share 
